Because of the rarity of childhood cancers, biopharmaceutical companies often don’t pursue therapies to treat these conditions. We spoke to Samuel Blackman, head of research and development for Day One Biopharmaceuticals, about childhood cancers, the need for precisions therapies, and Day One’s business model that makes targeting childhood cancers a priority. To listen to the full RareCast, click here: https://go.globalgenes.org/RC-Sam-Blackman #RareCast #GlobalGenes #ChildhoodCancers #Biopharma